195 related articles for article (PubMed ID: 25130892)
1. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
Kheir WJ; Sniegowski MC; El-Sawy T; Li A; Esmaeli B
Surv Ophthalmol; 2014; 59(5):493-502. PubMed ID: 25130892
[TBL] [Abstract][Full Text] [Related]
2. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Ho WL; Wong H; Yau T
Acta Ophthalmol; 2013 Nov; 91(7):604-9. PubMed ID: 22970709
[TBL] [Abstract][Full Text] [Related]
3. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
4. Update on ocular complications of systemic cancer chemotherapy.
Schmid KE; Kornek GV; Scheithauer W; Binder S
Surv Ophthalmol; 2006; 51(1):19-40. PubMed ID: 16414359
[TBL] [Abstract][Full Text] [Related]
5. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
[TBL] [Abstract][Full Text] [Related]
6. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
7. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients.
Hazin R; Abuzetun JY; Daoud YJ; Abu-Khalaf MM
Curr Opin Ophthalmol; 2009 Jul; 20(4):308-17. PubMed ID: 19491683
[TBL] [Abstract][Full Text] [Related]
8. [Recently recognized ophthalmic complications of systemic treatments].
Rousseau A; Labetoulle M
J Fr Ophtalmol; 2015 Nov; 38(9):876-82. PubMed ID: 26507783
[TBL] [Abstract][Full Text] [Related]
9. Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
Bhatti MT; Salama AKS
Eye (Lond); 2018 Feb; 32(2):287-301. PubMed ID: 29052609
[TBL] [Abstract][Full Text] [Related]
10. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.
Mellor JD; Cassumbhoy M; Jefford M
Asia Pac J Clin Oncol; 2011 Jun; 7(2):106-13. PubMed ID: 21585689
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
12. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
Fischer-Cartlidge EA
Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
[TBL] [Abstract][Full Text] [Related]
13. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
14. Side effects of targeted therapies. Introduction.
Eaby-Sandy B
Semin Oncol Nurs; 2014 Aug; 30(3):137-8. PubMed ID: 25085024
[No Abstract] [Full Text] [Related]
15. Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know?
Rohatgi S; Jagannathan JP; Rosenthal MH; Kim KW; Ramaiya NH; Krajewski KM
AJR Am J Roentgenol; 2014 Dec; 203(6):1353-62. PubMed ID: 25415715
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Reactions to Targeted Therapy.
Lee JJ; Kroshinsky D; Hoang MP
Am J Dermatopathol; 2017 Feb; 39(2):67-82. PubMed ID: 28134724
[TBL] [Abstract][Full Text] [Related]
17. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Liu S; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):863-75. PubMed ID: 26615131
[TBL] [Abstract][Full Text] [Related]
18. [Are targeted therapies better tolerated?].
Stiefelhagen P
MMW Fortschr Med; 2015 Apr; 157(7):23-4. PubMed ID: 26012443
[No Abstract] [Full Text] [Related]
19. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
